ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk.

摘要

The addition of high-sensitivity C-reactive protein (hs-CRP) measurements did not much improve conventional risk assessments in patients with hypertension and other cardiovascular (CV) risk factors in a post hoc analysis of an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) lipid-lowering arm.The lipid-lowering arm of ASCOT, which involved more than 10 000 patients, showed that atorvastatin therapy achieved significant reduction in major cardiovascular events in hypertensive patients with normal or modestly elevated low-density lipoprotein cholesterol (LDL-C) levels. Also, the combination of atorvastatin/ amlodipine as analysed in both the blood pressure-lowering and lipid arms of the ASCOT trial showed a greater reduction in non-fatal myocardial infarction (MI) and fatal coronary artery disease compared to patients receiving the ateno-lol-based therapy.